Eurofins enhances vaccine development services

Sandra Hageman, Director of Marketing, Eurofins BioPharma Services, Laboratory Testing, SandraHageman@eurofins.com

Vaccine development has historically been a long, complex process, requiring evaluation of immunogenicity, safety and protective efficacy. Given this complexity, many factors can affect the probability of licensure and ultimately, public health impact. The COVID-19 pandemic has shifted understanding of what’s possible in terms of fast-track vaccine development to address the public health emergency whilst maintaining standards of quality, safety and efficacy.

As experts in infectious disease assays, Eurofins Viracor BioPharma Services offer a broad array of testing solutions for biomarker detection, immunogenicity, and other safety and efficacy assessments to support anti-viral and clinical vaccine candidate programmes. Eurofins Viracor BioPharma supported the assay development, validation and testing of the Moderna mRNA-1273 COVID-19 vaccine candidate.

Eurofins Vaccine Development Services is comprised of Eurofins Viracor BioPharma Services, Eurofins Central Laboratory, Eurofins Bioanalytical Services and Eurofins CDMO; each company collaborates with each other and brings a unique set of capabilities to the mix to support vaccine development programmes from pre-clinical to human pharmacology studies (phase I trials), therapeutic exploratory studies (phase II), clinical vaccine efficacy and safety studies (phase III) and post authorisation surveillance studies (phase IV).

Further, Eurofins CDMO supports the development and manufacturing process of vaccine candidates for clinical trials worldwide.

Eurofins Vaccine Development Services supports multicenter, multi-country studies in over 85 countries worldwide. With large sample numbers distributed across many locations, the need for expert global logistics support to maintain specimen integrity, quick turnaround time of results and globally combinable data is key, and Eurofins companies are the go-to partners to support global vaccine development programmes. For more information, visit: www.eurofinscentrallaboratory.com/vaccine-development/